ABSTRACT
INTRODUCTION RimabotulinumtoxinB is a botulinum toxin produced by the bacterium Clostridium botulinum, previously named Botulinum Toxin type B. In 2009, in order to reinforce the individual biological potencies and the lack of interchangeability among the different botulinum toxin products, and to prevent medication errors, the U.S. Food and Drug Administration (FDA) has made changes to the drug names of the botulinum toxins (1,2). Thus came into being the new designation of RimabotulinumtoxinB for the Botulinum Toxin type B. The marketed trade names have not been changed, and thus RimabotulinumtoxinB is marketed as Myobloc in the USA, Canada, and Korea and as NeuroBloc in the European Union, Norway, and Iceland. At this time the European Union drug agency, European Medicines Agency (EMA), has not introduced the same changes to the drug names.
